| Argomenti e Notizie sull'Osteoporosi con raccolte bibliografiche su 
|
a cura del
Dott. C.Tarozzi Bologna Anno 18°
Num. 89 Recens. 1803 |
|
| Ricerca nell'archivio di questo sito... ? | ||
|
Kashiwagi H, Ono Y, Ohta M, Itoh S, Ichikawa F, Harada S, Takeda S, Sekiguchi N, Ishigai M, Takahashi T.
A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy.
Bioorg Med Chem. 2013 Apr 1;21(7):1823-33. doi: 10.1016/j.bmc.2013.01.042.
De Rosa G, Misso G, Salzano G, Caraglia M.
Bisphosphonates and cancer: what opportunities from nanotechnology?
J Drug Deliv. 2013;2013:637976. doi: 10.1155/2013/637976.
Abrahamsen B, Rubin KH, Eiken PA, Eastell R.
Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study.
Osteoporos Int. 2013 Jan;24(1):321-8.
Bruyère O, Fossi M, Zegels B, Leonori L, Hiligsmann M, Neuprez A, Reginster JY.
Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX® criteria.
Rheumatol Int. 2013 Apr;33(4):973-8.
Pichardo SE, Kuypers SC, Van Merkesteyn JP.
Denosumab osteonecrosis of the mandible: A new entity?A case report.
J Craniomaxillofac Surg. 2012 Dec 19.
Josse R, Khan A, Ngui D, Shapiro M.
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Curr Med Res Opin. 2013 Mar;29(3):205-16.
Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI.
Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
J Natl Cancer Inst. 2013 Feb 19.
A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy.
Bioorg Med Chem. 2013 Apr 1;21(7):1823-33. doi: 10.1016/j.bmc.2013.01.042.
Bisphosphonates and cancer: what opportunities from nanotechnology?
J Drug Deliv. 2013;2013:637976. doi: 10.1155/2013/637976.
Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study.
Osteoporos Int. 2013 Jan;24(1):321-8.
Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX® criteria.
Rheumatol Int. 2013 Apr;33(4):973-8.
Denosumab osteonecrosis of the mandible: A new entity?A case report.
J Craniomaxillofac Surg. 2012 Dec 19.
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Curr Med Res Opin. 2013 Mar;29(3):205-16.
Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
J Natl Cancer Inst. 2013 Feb 19.
Fazil M, Ali A, Baboota S, Sahni JK, Ali J.
Exploring drug delivery systems for treating osteoporosis.
Expert Opin Drug Deliv. 2013 Mar 29.
Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E.
Fracture risk and zoledronic acid therapy in men with osteoporosis.
N Engl J Med. 2012 Nov;367(18):1714-23.
Devold HM, Søgaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE.
Hip fracture and other predictors of anti-osteoporosis drug use in Norway.
Osteoporos Int. 2013 Apr;24(4):1225-33.
Cooper C, Adachi JD, Bardin T, Berenbaum F, Flamion B, Jonsson H, Kanis JA, Pelousse F, Lems WF, Pelletier JP, Martel-Pelletier J, Reiter S, Reginster JY, Rizzoli R, Bruyère O.
How to define responders in osteoarthritis.
Curr Med Res Opin. 2013 Apr 4.
Cupp ME, Song B, Kibler P, Raghavender US, Nayak SK, Thomsen W, Galande AK.
Investigating hydrophobic ligand-receptor interactions in parathyroid hormone receptor using peptide probes.
J Pept Sci. 2013 Apr 8. doi: 10.1002/psc.2502.
Srivastava K, Tyagi AM, Khan K, Dixit M, Lahiri S, Kumar A, Changkija B, Khan MP, Nagar GK, Yadav DK, Maurya R, Singh SP, Jain GK, Wahajuddin, Trivedi R, Chattopadhyay N, Singh D.
Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis.
Phytomedicine. 2013 Apr 15;20(6):470-80. doi: 10.1016/j.phymed.2012.12.021.
Exploring drug delivery systems for treating osteoporosis.
Expert Opin Drug Deliv. 2013 Mar 29.
Fracture risk and zoledronic acid therapy in men with osteoporosis.
N Engl J Med. 2012 Nov;367(18):1714-23.
Hip fracture and other predictors of anti-osteoporosis drug use in Norway.
Osteoporos Int. 2013 Apr;24(4):1225-33.
How to define responders in osteoarthritis.
Curr Med Res Opin. 2013 Apr 4.
Investigating hydrophobic ligand-receptor interactions in parathyroid hormone receptor using peptide probes.
J Pept Sci. 2013 Apr 8. doi: 10.1002/psc.2502.
Isoformononetin, a methoxydaidzein present in medicinal plants, reverses bone loss in osteopenic rats and exerts bone anabolic action by preventing osteoblast apoptosis.
Phytomedicine. 2013 Apr 15;20(6):470-80. doi: 10.1016/j.phymed.2012.12.021.
Herrera A, Lobo-Escolar A, Mateo J, Gil J, Ibarz E, Gracia L.
Male osteoporosis: A review.
World J Orthop. 2012 Dec 18;3(12):223-34. doi: 10.5312/wjo.v3.i12.223.
Ricciardi BF, Paul J, Kim A, Russell LA, Lane JM.
Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.
Osteoporos Int. 2013 Feb;24(2):423-32.
North RA, Jarvis MF.
P2X Receptors as Drug Targets.
Mol Pharmacol. 2013 Apr;83(4):759-69.
Robinson MK, Caminis J, Brunkow ME.
Sclerostin: How human mutations have helped reveal a new target for the treatment of osteoporosis.
Drug Discov Today. 2013 Apr 8. doi:pii: S1359-6446(13)00095-0. 10.1016/j.drudis.2013.04.001.
Sibilska I, Sicinski RR, Plum LA, Deluca HF.
Synthesis and biological activity of 25-hydroxy-2-methylene-vitamin D(3) compounds.
J Steroid Biochem Mol Biol. 2012 Dec 27.
Maximov PY, Lee TM, Jordan VC.
The discovery and development of Selective Estrogen Receptor Modulators (SERMs) for clinical practice.
Curr Clin Pharmacol. 2012 Oct 4.
Lippuner K.
The future of osteoporosis treatment - a research update.
Swiss Med Wkly. 2012 Jul 19;142:w13624.
Malan J, Ettinger K, Naumann E, Beirne OR.
The relationship of denosumab pharmacology and osteonecrosis of the jaws.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-6.
Male osteoporosis: A review.
World J Orthop. 2012 Dec 18;3(12):223-34. doi: 10.5312/wjo.v3.i12.223.
Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.
Osteoporos Int. 2013 Feb;24(2):423-32.
P2X Receptors as Drug Targets.
Mol Pharmacol. 2013 Apr;83(4):759-69.
Sclerostin: How human mutations have helped reveal a new target for the treatment of osteoporosis.
Drug Discov Today. 2013 Apr 8. doi:pii: S1359-6446(13)00095-0. 10.1016/j.drudis.2013.04.001.
Synthesis and biological activity of 25-hydroxy-2-methylene-vitamin D(3) compounds.
J Steroid Biochem Mol Biol. 2012 Dec 27.
The discovery and development of Selective Estrogen Receptor Modulators (SERMs) for clinical practice.
Curr Clin Pharmacol. 2012 Oct 4.
The future of osteoporosis treatment - a research update.
Swiss Med Wkly. 2012 Jul 19;142:w13624.
The relationship of denosumab pharmacology and osteonecrosis of the jaws.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-6.
questo sito aderisce ai principi HONCODE disclaimer